Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B Vaccine in CLL/SLL Patients
NCT03685708Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by National Heart, Lung, and Blood Institute. Started Dec 2018; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03685708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685708.